Inclusion Criteria:

          -  Patients must be 18 years of age and older.

          -  Pathologically confirmed SCCHN, not previously treated, with a plan to undergo surgery

          -  Patients who have stage III-IV disease without distant metastases (M0) of 1) oral
             cavity, 2) larynx, 3) hypopharynx 4) oropharynx (human papillomavirus [HPV] neg) using
             American Joint Committee on Cancer (AJCC) 8th edition

          -  Patients who have oropharyngeal cancer that HPV positive, stage II-III disease without
             distant metastases (M0) using AJCC 8th edition

          -  All patients with oropharyngeal SCCHN must be tested for HPV (by p16 and/or HPV in
             situ hybridization [ISH] or polymerase chain reaction [PCR])

          -  Patients must be evaluated by a head and neck surgeon and be deemed surgically
             resectable at baseline

          -  Tumor sample must be available for HPV p16 and PD-L1 testing and if oropharyngeal,
             must be tested for HPV p16

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1

          -  While blood cells 2000/ul or more

          -  Absolute neutrophil count 1500/ul or more

          -  Platelets 100,000/ul or more

          -  Hemoglobin 9 g/dl or more; (transfusion permitted)

          -  Bilirubin less than or equal to 1.5 x the upper limit of normal (except subjects with
             Gilbert syndrome, who can have total bilirubin < 3 mg/dl)

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal
             to 3 x the upper limit of normal

          -  Glomerular filtration rate (GFR) greater than or equal to 40 ml/min using the
             Cockcroft-Gault formula or serum creatinine less than or equal to 1.5 x upper limit of
             normal (ULN)

          -  Women of reproductive potential should have a negative serum or urine pregnancy test
             (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin
             [HCG]) within 21 days of study enrollment

          -  Women of reproductive potential must use highly effective contraception methods to
             avoid pregnancy for 23 weeks after the last dose of study drugs; "women of
             reproductive potential" is defined as any female who has experienced menarche and who
             has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or
             who is not postmenopausal; menopause is defined clinically as 12 months of amenorrhea
             in a woman over 45 in the absence of other biological or physiological causes; in
             addition, women under the age of 55 must have a documented serum follicle stimulating
             hormone (FSH) level less than 40 mIU/mL

          -  Men of reproductive potential who are sexually active with women of reproductive
             potential must use any contraceptive method with a failure rate of less than 1% per
             year; men who are receiving the study medications will be instructed to adhere to
             contraception for 31 weeks after the last dose of study drugs; men who are azoospermic
             do not require contraception

          -  All subjects must be able to comprehend and sign a written informed consent document

        Exclusion Criteria:

          -  Primary nasopharyngeal carcinoma

          -  Patients who have participated in a study with an investigational agent or device
             within 2 weeks of initiation of treatment

          -  Any prior radiotherapy to the neck

          -  Any prior treatment for SCCHN

          -  Any prior therapy with anti-PD-1, anti-PD-L2, anti-CTLA-4 antibody, or any other
             antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint
             pathways

          -  Any history of a sever hypersensitivity reaction to any monoclonal antibody

          -  Any history of allergy to the study drug components

          -  Any concurrent malignancies- exceptions include- basal cell carcinoma of the skin,
             squamous cell carcinoma of the skin, superficial bladder cancer or in situ cervical
             cancer that has undergone potentially curative therapy; patients with a history of
             other prior malignancy must have been treated with curative intent and must have
             remained disease-free for 3 years post-diagnosis

          -  Any diagnosis of immunodeficiency or current immunosuppressive therapy including
             >10mg/day of prednisone within 14 days of enrollment is not permitted (excludes
             emergency transient steroid use at discretion of the treating physician).

          -  Patients that have an active autoimmune disease requiring systemic treatment within
             the past 3 months or a documented history of clinically severe autoimmune disease, or
             a syndrome that requires systemic steroids (> 10 mg daily prednisone equivalents) or
             immunosuppressive agents. Subjects with vitiligo, type I diabetes mellitus, or
             resolved childhood asthma/atopy would be an exception to this rule. Inhaled or topical
             steroids, and adrenal replacement steroid doses ≤10 mg daily prednisone equivalent,
             are permitted in the absence of active autoimmune disease. Subjects with
             hypothyroidism stable on hormone replacement or Sjorgen's syndrome will not be
             excluded from the study.

          -  Patients with a known human immunodeficiency virus infection (HIV 1/2 antibodies) or
             acquired immunodeficiency syndrome (HIV/AIDS), active hepatitis B (e.g., hepatitis B
             surface antigen [HBsAg] reactive) or hepatitis C (e.g., hepatitis C virus [HCV]
             ribonucleic acid [RNA] [qualitative] is detected)

          -  Patients with evidence of non-infectious pneumonitis or history of interstitial lung
             disease

          -  Patients who have received a live vaccine within 30 days prior initiation of the
             systemic regimen

          -  Patients must not be receiving any other investigational agents

          -  Patients with uncontrolled intercurrent illnesses including, but not limited to an
             active infection requiring systemic therapy or a known psychiatric or substance abuse
             disorder(s) that would interfere with cooperation with the requirements of the trial

          -  Women must not be pregnant (as above) or breastfeeding